<DOC>
	<DOCNO>NCT01677624</DOCNO>
	<brief_summary>To evaluate efficacy safety transcatheter arterial embolization E7040 Japanese subject hypervascular tumor arteriovenous malformation</brief_summary>
	<brief_title>A Multicenter , Open-label Study E7040 Japanese Subjects With Hypervascular Tumor Subjects With Arteriovenous Malformation</brief_title>
	<detailed_description />
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Arteriovenous Malformations</mesh_term>
	<mesh_term>Hemangioma</mesh_term>
	<criteria>Inclusion criterion : 1 . Subjects subject follow vascular embolization therapy 1 . Subjects hepatocellular carcinoma ( HCC ) deep stain early stage tumor confirm dynamic computerized tomography ( CT ) bolus intravenous infusion contrast medium typical find hypervascular tumor , amenable resection local therapy , meet follow ( ) ( c ) . 1 . 1 lesion &gt; 50 mm diameter 2 . 2 3 lesion &gt; 30 mm least one diameter 3 . 4 lesion 2 . Metastatic hepatic cancer Subjects metastatic hepatic cancer deep stain early stage tumor confirm dynamic CT bolus intravenous infusion contrast medium typical find hypervascular tumor amenable resection , whose primary lesion extrahepatic lesion control . 3 . Hypervascular tumor metastatic hepatic cancer Subjects deep stain early stage tumor confirm dynamic CT bolus injection contrast medium typical find hypervascular tumor liver ( e.g. , renal cell carcinoma , bone soft tissue sarcoma ) meet follow ( ) ( b ) . 1 . Subjects applicable preoperative arterial embolization therapy reduce tumor size volume bleed safe conduct surgical resection local therapy ( e.g. , radiofrequency ablation ( RFA ) ) 2 . Subjects stable general condition applicable pain control treatment 4 . Arteriovenous malformation : Subjects arteriovenous malformation ( except central nervous system , heart , lung ) confirm dynamic CT low risk undesirable reflux systemic circulation vessel malformation suitable particle embolization size 2 . Subjects Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 02 ( PS 01 metastatic hepatic cancer ) 3 . No carryover effect prior therapy adverse drug reaction may influence embolic effect E7040 , history prior therapy time elapsed end prior therapy start E7040 embolization therapy : Surgery : great equal 6 week Local therapy : great equal 4 week Embolization nontarget vessel : great equal 4 week 4 . With survival great equal 12 month prior arterial embolization therapy use E7040 Exclusion criterion : 1 . Subjects clinical symptom brain metastasis cerebral encephalopathy require medical treatment 2 . Suspected hepatocellular carcinoma ( HCC ) judge clinical finding patient disease HCC 3 . Previously treat arterial embolization therapy target vessel 4 . Previously treat arterial embolization therapy nontarget vessel , resection target organ , local therapy ( e.g. , RFA ) ( except HCC patient ) 5 . Subjects expect arterypulmonary vein shunt righttoleft shunt , possible risk influx embolized particle central nervous system .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Hypervascular tumor</keyword>
	<keyword>arteriovenous malformation</keyword>
	<keyword>arterial embolization</keyword>
</DOC>